Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRFS Grifols	$10.78 +0.7%	$9.19	$6.19 ▼ $11.14	$7.36B	0.56	1.32 million shs	1.33 million shs
NUVL Nuvalent	$77.76 -0.8%	$78.69	$55.53 ▼ $113.51	$5.63B	1.3	463,959 shs	376,599 shs
TGTX TG Therapeutics	$35.02 -1.4%	$36.83	$16.65 ▼ $46.48	$5.64B	1.95	1.51 million shs	2.32 million shs
VCEL Vericel	$35.63 +2.0%	$40.83	$33.09 ▼ $63.00	$1.76B	1.32	600,352 shs	962,793 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRFS Grifols	+0.75%	+6.73%	+17.94%	+46.67%	+44.31%
NUVL Nuvalent	-0.75%	-4.48%	-3.40%	+0.39%	-2.73%
TGTX TG Therapeutics	-1.35%	-5.09%	-3.50%	-19.38%	+77.23%
VCEL Vericel	+1.97%	-11.19%	-14.06%	-8.52%	-29.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GRFS Grifols	3.1017 of 5 stars	1.5	4.0	0.0	2.0	0.0	5.0
NUVL Nuvalent	3.2027 of 5 stars	4.5	1.0	0.0	2.8	3.3	0.0
TGTX TG Therapeutics	4.0843 of 5 stars	3.4	0.0	3.5	2.9	2.5	1.9
VCEL Vericel	2.3238 of 5 stars	3.5	0.0	0.0	3.3	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GRFS Grifols	3.00	Buy	$10.30	-4.45% Downside
NUVL Nuvalent	3.09	Buy	$119.60	53.81% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$43.80	25.07% Upside
VCEL Vericel	3.00	Buy	$59.86	68.00% Upside

Current Analyst Ratings Breakdown

Latest VCEL, GRFS, TGTX, and NUVL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	VCEL Vericel	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $58.00
7/21/2025	NUVL Nuvalent	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$115.00
7/10/2025	TGTX TG Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$37.00
6/30/2025	NUVL Nuvalent	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	NUVL Nuvalent	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$105.00 ➝ $112.00
6/24/2025	NUVL Nuvalent	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$115.00
6/24/2025	NUVL Nuvalent	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$125.00 ➝ $140.00
6/24/2025	NUVL Nuvalent	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$110.00 ➝ $130.00
6/17/2025	GRFS Grifols	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.60 ➝ $10.30
6/16/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00
5/22/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00 ➝ $67.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GRFS Grifols	$7.81B	0.95	$0.94 per share	11.43	$12.55 per share	0.86
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A
TGTX TG Therapeutics	$329M	16.90	$0.12 per share	295.93	$1.43 per share	24.49
VCEL Vericel	$249.12M	7.20	$0.32 per share	111.81	$6.09 per share	5.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GRFS Grifols	$169.80M	$1.17	9.21	10.27	0.37	N/A	N/A	N/A	N/A
NUVL Nuvalent	-$260.76M	-$4.39	N/A	N/A	N/A	N/A	-31.35%	-29.27%	8/14/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	145.92	35.02	N/A	10.13%	18.88%	7.05%	8/4/2025 (Estimated)
VCEL Vericel	$10.36M	$0.12	296.94	80.98	N/A	2.85%	2.47%	1.69%	N/A

Latest VCEL, GRFS, TGTX, and NUVL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	NUVL Nuvalent	-$1.27	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	TGTX TG Therapeutics	$0.27	N/A	N/A	N/A	$147.76 million	N/A
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/8/2025	Q1 2025	VCEL Vericel	-$0.09	-$0.23	-$0.14	-$0.23	$53.86 million	$52.60 million
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GRFS Grifols	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Latest VCEL, GRFS, TGTX, and NUVL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	GRFS Grifols	--	$0.1404		8/12/2025	8/12/2025	8/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GRFS Grifols	1.20	2.64	0.97
NUVL Nuvalent	N/A	14.48	14.48
TGTX TG Therapeutics	1.03	4.02	3.04
VCEL Vericel	N/A	4.97	4.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GRFS Grifols	N/A
NUVL Nuvalent	97.26%
TGTX TG Therapeutics	58.58%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
GRFS Grifols	0.19%
NUVL Nuvalent	10.20%
TGTX TG Therapeutics	10.64%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GRFS Grifols	23,822	687.55 million	686.25 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable
VCEL Vericel	300	50.34 million	47.73 million	Optionable

VCEL, GRFS, TGTX, and NUVL Headlines

Recent News About These Companies

Vericel (NASDAQ:VCEL) Hits New 52-Week Low - Here's What Happened

August 2 at 10:42 AM | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Q2 2025 Earnings Call Transcript

August 2 at 3:45 AM | msn.com

Vericel Corporation Reports Strong Q2 2025 Earnings

August 1 at 8:59 PM | tipranks.com

Vericel (NASDAQ:VCEL) Shares Gap Down - Here's What Happened

August 1 at 1:11 PM | marketbeat.com

Earnings To Watch: Vericel Corp (VCEL) Reports Q2 2025 Result

August 1 at 2:09 AM | finance.yahoo.com

Vericel Corporation (VCEL) Q2 2025 Earnings Call Transcript

August 1 at 2:09 AM | seekingalpha.com

Vericel Corporation Reports Strong Q2 2025 Results

July 31 at 12:41 AM | tipranks.com

Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates

July 31 at 10:16 AM | zacks.com

Vericel Reports Second Quarter 2025 Financial Results

July 31 at 8:08 AM | globenewswire.com

Vericel Corporation (NASDAQ:VCEL) Shares Bought by Federated Hermes Inc.

July 31 at 3:22 AM | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in Vericel Corporation (NASDAQ:VCEL)

July 31 at 3:22 AM | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Meeder Asset Management Inc.

July 30 at 3:07 AM | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Receives $61.14 Consensus Price Target from Analysts

July 30 at 2:07 AM | americanbankingnews.com

Bryce Point Capital LLC Invests $478,000 in Vericel Corporation (NASDAQ:VCEL)

July 28, 2025 | marketbeat.com

Knights of Columbus Asset Advisors LLC Decreases Stake in Vericel Corporation (NASDAQ:VCEL)

July 27, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Buy" by Analysts

July 27, 2025 | marketbeat.com

Vericel Corporation (VCEL): A Bull Case Theory

July 24, 2025 | insidermonkey.com

Vericel Corporation (VCEL): A Bull Case Theory

July 24, 2025 | msn.com

Vericel (VCEL) Projected to Post Earnings on Thursday

July 24, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Bought by Victory Capital Management Inc.

July 22, 2025 | marketbeat.com

Envestnet Asset Management Inc. Has $9.13 Million Holdings in Vericel Corporation (NASDAQ:VCEL)

July 22, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL, GRFS, TGTX, and NUVL Company Descriptions

Grifols NASDAQ:GRFS

$10.78 +0.08 (+0.75%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.78 0.00 (0.00%)

As of 08/1/2025 04:04 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Nuvalent NASDAQ:NUVL

$77.76 -0.59 (-0.75%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$77.76 -0.01 (-0.01%)

As of 08/1/2025 07:55 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$35.02 -0.48 (-1.35%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$35.33 +0.31 (+0.87%)

As of 08/1/2025 08:00 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Vericel NASDAQ:VCEL

$35.63 +0.69 (+1.97%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$34.84 -0.79 (-2.20%)

As of 08/1/2025 07:02 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time